Lupin Gets USFDA Observations for Pithampur Plant

Sep 28, 2024 16:06

Lupin receives six observations from the USFDA following an inspection of its Pithampur plant in Madhya Pradesh. The company is addressing the observations and will respond within the stipulated timeframe.

New Delhi, Sep 28 (PTI) Drug firm Lupin on Saturday said the US health regulator has issued six observations after inspecting its Madhya Pradesh-based manufacturing facility.

The US Food and Drug Administration (USFDA) inspected the company's Pithampur Unit-1 API and finished product manufacturing facility from September 16 to September 27, 2024, Lupin said in a regulatory filing.

The inspection closed with three observations each on the API and finished product side, it added.

"We are addressing the observations comprehensively and will respond to the US FDA within the stipulated timeframe," the Mumbai-based drug maker said.

Source: PTI

MORE NEWS

Amul Turnover Rises 8% to Rs 59,445 Cr in FY24

GCMMF, the operator of Amul brand, reports an 8% increase in turnover to Rs 59,445...

REC Raises USD 500 Million via Green Bond

REC Ltd has raised USD 500 million through green dollar bonds to finance renewable...

Agri Startups Training: Chouhan Calls for...

Agriculture Minister Shivraj Singh Chouhan emphasizes the importance of training for...

Rice Export Ban Lifted: Relief for Bengal...

India lifts ban on non-basmati white rice exports, bringing relief to Bengal's...

India SME Forum Launches 'Start Exporting in...

India SME Forum launches 'Start Exporting in Eight Weeks' program to help MSMEs access...

DPIIT to Decriminalise Minor Offences with Jan...

DPIIT is working on 100 rules to decriminalise minor offenses under Jan Vishwas 2.0,...

Meesho Festive Sale: 6.5 Cr Visitors, Orders...

Meesho's 'Mega Blockbuster Sale' sees a record-breaking 6.5 crore unique visitors on...

Emerald Haven Realty Acquires Land in...

Emerald Haven Realty has acquired two land parcels in North Bengaluru and Chennai,...

Zydus Gets USFDA Approval for Generic Prostate...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide capsules (40...

Biocon Gets USFDA Observations for Bengaluru...

Biocon's Bengaluru-based API facility received four observations from the USFDA...

Lupin Gets USFDA Observations for Pithampur Plant

You May Like To Read

MORE NEWS